(UTAHPEOPLESPOST) — After conducting serveral clinical trials on patients with Hodgkin’s Lymphoma, researchers believe that nivolumab is the new weapon against cancer.
Experts report a breakthrough regarding Hodgkin’s Lymphoma after conducting a clinical trial on patients with resistant forms of the disease. This new compound used in the clinical trial, allows the immune system to efficiently recognize and destroy cancer cells and showed great promise in 87 percent of the patients. Reports show that the patients’ tumors were in complete or partial remission after participating in this clinical trial.
The results of this trial present the most important evidence to date of the potential treatments that can increase the capability of the immune system to attack and successfully kill cancer cells. Clinical trials conducted by using these immunotherapy techniques in other types of cancer have made them very effective in some groups of patients, this new study is different because almost all patients received the same treatement.
